What is the primary purpose of ex vivo cardiac safety assessments?

Ex vivo cardiac safety assessments are designed to evaluate the safety and potential cardiotoxic effects of new drugs on cardiac tissues, ensuring patient safety during clinical trials.

How do ex vivo assessments differ from in vivo assessments?

Ex vivo assessments focus on specific heart tissues in a controlled laboratory environment, while in vivo assessments involve whole living organisms which can introduce more variability.

Are ex vivo cardiac safety assessments sufficient for regulatory submissions?

While ex vivo assessments provide valuable safety data, they are typically part of a comprehensive safety evaluation strategy, which may include both in vitro and in vivo studies to meet regulatory requirements.